WuXi Biologics: Ireland’s largest single-use facility underway

By Flora Southey contact

- Last updated on GMT

WuXi Biologics' facility in Dundalk, Ireland
WuXi Biologics' facility in Dundalk, Ireland

Related tags: Wuxi biologics, Ireland, Contract manufacturing

The CDMO has broken ground on its first site outside of China – a €325m single-use manufacturing facility in County Louth, Ireland.

Construction has commenced at WuXi Biologics’ Irish facility​, where the contract development and manufacturing organisation (CDMO) will make biologic drugs for commercial production.

The 26-hectare campus will house 48,000L fed-batch and 6,000L perfusion bioreactor capacity, with single-use and continuous bioprocessing capabilities.

Supported by the Republic of Ireland’s Industrial Development Authority (IDA), the €325m ($390m) project is located on the government agency’s greenfield site in Mullagharlin, Dundalk.

According to WuXi Biologics CEO Chris Chen, Ireland’s European Union (EU) membership makes it an attractive option for investment, as the UK prepares to leave the union.

Ireland’s proximity to mainland Europe provides the CDMO “access to [the] EU market,” ​he told us in May of this year.

Global expansion

While the Dundalk facility marks WuXi Biologics’ first outside of China, the firm has plans to build global facilities in Singapore​ and the US​.

The CDMO is also expanding its site network within China. Last month, WuXi Biologics broke ground on a 1.6 million-square-foot Biologics Innovation Center​ in Shanghai, as well as on a $240m manufacturing site​ near Beijing.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more